key: cord-0687689-nksd3wuw
authors: Woo, Marcel S; Malsy, Jakob; Pöttgen, Jana; Zai, Susan Seddiq; Ufer, Friederike; Hadjilaou, Alexandros; Schmiedel, Stefan; Addo, Marylyn M; Gerloff, Christian; Heesen, Christoph; Schulze zur Wiesch, Julian; Friese, Manuel A
title: Frequent neurocognitive deficits after recovery from mild COVID-19
date: 2020-11-23
journal: Brain Commun
DOI: 10.1093/braincomms/fcaa205
sha: 4e29530f381ea3618f741d3ef098f68855e348f5
doc_id: 687689
cord_uid: nksd3wuw

Neuropsychiatric complications associated with coronavirus disease 2019 caused by the Coronavirus SARS-CoV-2 (COVID-19) are increasingly appreciated. While most studies have focused on severely affected individuals during acute infection it remains unclear whether mild COVID-19 results in neurocognitive deficits in young patients. Here, we established a screening approach to detect cognitive deficiencies in post-COVID-19 patients. In this cross-sectional study, we recruited 18 mostly young patients 20 to 105 days (median 85 days) after recovery from mild to moderate disease who visited our outpatient clinic for post-COVID-19 care. Notably, 14 (78%) patients reported sustained mild cognitive deficits and performed worse in the Modified Telephone Interview for Cognitive Status (TICS-M) screening test for mild cognitive impairment compared to 10 age-matched healthy controls. While short-term memory, attention and concentration were particularly affected by COVID-19, screening results did not correlate with hospitalisation, treatment, viremia or acute inflammation. Additionally, TICS-M scores did not correlate with depressed mood or fatigue. In two severely affected patients we excluded structural or other inflammatory causes by magnetic resonance imaging, serum and cerebrospinal fluid analyses. Together, our results demonstrate that sustained subclinical cognitive impairments might be a common complication after recovery from COVID-19 in young adults, regardless of clinical course that were unmasked by our diagnostic approach.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019 (COVID-19) (Huang et al., 2020) .

While COVID-19 patients frequently suffer from respiratory symptoms, neurologic and neuropsychiatric complications have been increasingly reported (Ellul et al., 2020; Varatharaj et al., 2020) . Moreover, histopathologic examination of brains from deceased COVID-19 patients indicate the potential of SARS-CoV-2 to infiltrate the central nervous system (CNS) (Solomon et al., 2020) .

Reported neuropsychiatric manifestations include milder symptoms like dizziness and anosmia (Hornuss et al., 2020) but also in rare cases severe manifestations such as acute demyelinating encephalopathy (Reichard et al., 2020) , meningitis (Moriguchi et al., 2020) , and strokes (Helms et al., 2020; Oxley et al., 2020) . Recently, the symptoms of 153 COVID-19 patients from the United Kingdom who reported neurologic and psychiatric complications during the acute phase of the disease were reported and intracerebral haemorrhages and altered mental status were the most common complications (Varatharaj et al., 2020) . Similarly, in a study from Wuhan with 214 patients, 78 patients reported unspecific neurological symptoms and 13 patients had a new cerebrovascular diagnosis during acute infection (Mao et al., 2020) .

These studies have focused on severe neurologic and neuropsychiatric complications during the acute infection but did not include sustained neuropsychological deficits after full recovery from COVID-19. Moreover, severe neurologic complications have been mostly investigated in patients with multiple risk factors who developed severe COVID-19 with complications but not in young adults after recovery. For the outbreaks of the closely related SARS-CoV and middle-east-respiratory-syndrome-coronavirus (MERS-CoV) acute delirium and encephalitis have been reported during acute disease but also sustained neuropsychologic syndromes (Rogers et al., 2020) . Thus, deeper analysis and epidemiologic (Ritchie et al., 2020) studies as well as development of screening tools for mild cognitive deficits in young adults are an important unmet clinical need to detect subclinical neuropsychologic symptoms and help to differentiate unspecific post-illness-manifestations.

Here, we established a facile screening approach for cognitive deficits in 18 young patients without diagnosed cognitive preconditions after recovery from COVID-19 and discovered widespread subclinical deficits.

For this cross-sectional study, we randomly interviewed patients from the outpatient clinic of the University Medical Centre Hamburg-Eppendorf (UKE) and only included patients who did not stay at intensive care unit. In total, 21 patients were approached and 18 agreed to participate in our study. The severity of COVID-4 19 into mild, moderate, severe, critical and lethal disease courses was classified using the WHO criteria (WHO reference number: 451 WHO/2019-nCoV/clinical/2020.5). We only included patients who suffered from mild and moderate COVID-19 and were not admitted to our intensive care unit. Since our patient cohort was considerably younger (mean age 42.2; SD 14.3 years) we additionally tested healthy individuals with similar age (mean age 38.4; SD 14.4 years). Healthy individuals were randomly selected employees of the University Medical Center Hamburg-Eppendorf who did not have prior knowledge of the TICS-M or similar neuropsychological screenings and were matched for age within a range of five years but not for sex. Except for one patient who still visited high school, all patients and healthy participants received in total more than 12 years of education. The patient reported symptoms were collected by individual reports and documented symptoms during the inpatient and subsequent outpatient stays at the University Medical Center Hamburg-Eppendorf. During the interviews, we questioned the patients in a structured manner that included all organ systems and specifically asked for neuropsychological deficits.

The interviews were either conducted by phone or directly with the patient. Individuals were recruited until July 14 th , 2020. To sensitively screen for mild cognitive deficiencies, we utilised the Modified Telephone Interview for Cognitive Status (TICS-M) that was originally developed to broadly screen for mild cognitive impairment in elderly adults (MCI) by telephone. This questionnaire has been validated for amnestic mild cognitive impairment (reference for mean age 74.9, < 34 amnestic mild cognitive impairment) (Cook et al., 2009 ) and Alzheimer's dementia (Manly et al., 2011) . We performed TICS-M according to published protocols (Cook et al., 2009) . The total interview lasted 15 to 20 minutes. Four domains are tested by the TICS-M: (1) orientation, (2) recent memory and delayed memory, (3) attention and (4) semantic memory, comprehension and repetition (language/concentration) (De Jager et al., 2003) . The TICS-M included the following items: (1) name, (2) age, (3) date, (4) weekday, (5) season, (6) phone number (each 1 point); (7) counting backward (2 points); (8) first, a 10-word list learning exercise and then a delayed (21) recall of that word list (10 points each); (9) subtractions (5 points); (10-13) responsive naming (4 points); (14-15) repetition (2 points); (16) current chancellor and (17) president of Germany (each 2 points); (18) finger tapping (2 points), and (19-20) word opposites (2 points). The total score was 50 points. The TICS-M score has been validated to test episodic memory for words, episodic memory for non-verbal information and attention (Crooks et al., 2006) . We controlled for possible biases by the Patient Health Questionnaire-9 

We used Cobas6800 system (Roche, Mannheim, Germany) for detection of SARS-CoV-2 RNA from nasopharyngeal smears by polymerase-chain-reaction as previously described in detail (Pfefferle et al., 2020) . For serology we used Liaison XL system for quantitative SARS-CoV-2 IgG detection according to the manufacturer recommendation.

Data was analysed within the R environment (Version 1.2.5.002) on a Mac OS X. Unless stated otherwise comparisons between two experimental groups are presented as violin plot with median or 95% confidence intervals and differences were determined using two-tailed, unpaired Wilcoxon-Mann-Whitney-test and were FDR-corrected for multiple comparisons. To find predictors of screening results we used multiple linear regression models. The results were FDR-corrected for multiple comparisons. Exact P-values are reported in respective sections of the article and figure legends. We analysed the scores of FAS and PHQ-9 as well as age, length of hospitalisation, sickness duration, time from recovery to neurocognitive assessment, maximal PCR ct values, maximal antibody titres, maximal CRP, IL-6, ferritin and D-dimers as predictors. The outcome variable was the TICS-M score. For effect size of non-parametric comparisons, we calculated Rosenthals r. Significant results are indicated by *P < 0.05, **P < 0.01, ***P < 0.001.

The study was approved by the Ärztekammer Hamburg. All patients and healthy participants gave consent for participation, data analysis and publication.

Data are available from the corresponding author, upon reasonable request. Data are not publicly available due to ethical restrictions because their containing information could compromise the privacy of the reported patients.

The aim of this study was to establish a screening that sensitively and specifically detects subtle neurocognitive deficits. Therefore, we screened our post-COVID-19 outpatient clinic for mostly young patients with mild to moderate disease courses according to the WHO criteria (WHO reference number: 451 WHO/2019-nCoV/clinical/2020.5) without known cognitive preconditions who recovered without complications. We included 10 females and 8 males at ages ranging from 17 to 71 years (mean 42.2 years, SD 14.3 years). Our cohort consisted of 11 inpatients (61%), 6 outpatients (33%) and 1 patient did not seek medical care (6%). During the acute infection four patients received supplementary oxygen, two patients were treated with remdesivir and one patient with tocilizumab due to cytokine storm. None of the patients received intensive care and no vascular or structural neurological event was recorded. All patients recovered without severe complications 20 to 105 days (median 85 days from COVID-19 recovery to assessment time) prior to the timepoint of our screening (a summary of patients' characteristics is provided in Table 1 ).

In addition, we tested ten healthy individuals with similar age (n = 10, mean age 38.4 years, SD 14.4 years; a summary of healthy controls' characteristics is provided in Table 1) Figure 1B) . Notably, results from screening for depression (Personal Health Questionnaire 9) and for fatigue (Fatigue Assessment Scale) did not show significant correlation with TICS-M scores ( Figure 1C and D). In terms of patient self-reported symptoms, out of 18 included individuals nine (50%) reported attention deficits, eight (44.4%) concentration deficits, eight (44.4%) short term memory deficits, five (27.8%) troubles in finding words, three (16.7%) fatigue, two (11.1%) severe mood swings, and one (5.6%) sustained lack of energy, phonophobia, incoherent thoughts ( Figure 1E ).

Next, we aimed to find predictors of our observed cognitive deficits. First, we analysed patient characteristics and found that neither sex (Figure 2A) , nor age ( Figure 2B ) could explain the observed differences. Additionally, we investigated whether severity of the acute COVID-19 disease could be an explanation. Therefore, we next analysed whether hospitalisation had an impact on post-COVID-19

manifestations. However, we found that TICS-M scores in post-COVID-19 patients did not correlate with the time interval from our interview to recovery ( Figure 2C ), length of sickness ( Figure 2D ) and length of inpatient stay ( Figure 2E ). To further evaluate the impact of disease severity, we correlated the 7 neurocognitive deficits with acute and sustained somatic symptoms ( Figure 2F ) and treatments during the acute infection. Our analysis revealed that the number of somatic symptoms did not correlate with the number of sustained self-reported neurocognitive deficits ( Figure 2G ) and the results in our screening ( Figure 2H) . Moreover, treatments such as oxygen supplementation ( Figure 3A ) and drugs like remdesivir, tocilizumab or antibiotics ( Figure 3B ) in acute infection could not predict the observed cognitive impairments. Thus, our data implies that post-COVID-19 neuropsychologic deficits are independent from hospitalisation and disease severity.

Subsequently, we analysed the impact of acute inflammation and maximal viremia in acute COVID-19 on neurocognitive deficits. Therefore, we accounted the cycle threshold (Ct) from SARS-CoV-2 PCR, antibodies against SARS-CoV-2 and inflammatory serum markers. Our analysis revealed that maximal SARS-CoV-2 IgG-titres ( Figure 3C 

the whole body (Varga et al., 2020) . Thus, a multitude of symptoms and clinical disease courses have been described (Gupta et al., 2020) . Here, we focused on the evaluation of neurocognitive post-COVID-19 manifestations in mostly young adults who recovered from acute uncomplicated COVID-19. This study demonstrates substantial neurocognitive deficits that sustain after recovery and advocate screening routines for cognitive deficits during medical care of post-COVID-19 patients.

Cerebrovascular events and altered mental status have been described to be common neuropsychiatric manifestations in acute COVID-19 in a nationwide surveillance study in the UK (Varatharaj et al., 2020) . 59% of patients with altered mental status could be assigned to a neuropsychiatric disorder, underlining the diversity of COVID-19 associated manifestations. We screened patients after recovery from COVID-19 and found substantial neurocognitive deficits that sustained after acute infection.

Moreover, we detected subtle cognitive deficits that did not restrain most patients in daily life and were only unmasked by our specific screening, including deficits in short term memory, attention and concentration. Retrospective meta-analysis of SARS and MERS outbreaks have revealed acute and longterm neuropsychological deficits. Similar to our findings, most-common post-illness manifestations 8 included impaired concentration and attention in 19.9% and impaired memory in 18.9% of patients after recovery (Rogers et al., 2020) . Therefore, our study represents first indications that warrant broad screenings in post-COVID-19 patients to clarify the diversity of neuropsychological deficits and prevent potential further harm.

Screening methods for mild cognitive deficits are mostly used in the diagnostics of dementia that were validated in elderly adults (Castanho et al., 2014) . Here, we chose TICS-M as it has been validated as a telephone screening method which is important for prospective studies that include patients who did not seek professional medical care during or after COVID-19. However, TICS-M has been validated for the diagnosis of mild amnestic dementia in a patient cohort with an average age of 74.9 years (Cook et al., 2009 ). Since the average age of our patient cohort (42.1 years) was considerably lower, we additionally tested a healthy control group with similar age as control. Thus, further optimization of a standardized screening tool is needed. Our findings suggest to especially focus the screening on short-term memory, attention and concentration. In contrast to currently available screening tools validation should include all age groups since we and others (Dinakaran et al., 2020; Nalleballe et al., 2020) observed neurocognitive deficits in young adults.

Post-viral-syndromes have been described for multiple viral infections, such as Epstein-Barr-Virus or influenza (Hotchin et al., 1989) and are characterised by severe fatigue (Thomas, 1987) .

Smartphone-App based patient-reports assessing fatigue in COVID-19 (Menni et al., 2020) and histopathological findings of viral infiltrates and diffuse immune cell activation in brains from deceased COVID-19 patients (Polak et al., 2020 ) may indicate similar clinical presentations. However, systematic analysis with large patient cohorts in different cultural settings and different countries are needed for clarification. To exclude potential biases and classical post-viral-syndromes, we additionally screened for fatigue and depression. Our data indicate that neurocognitive deficits after recovery from COVID-19 are independent from fatigue and mood alterations and therefore might be different from the classical postviral-syndrome (Perrin et al., 2020 ) but a specific post-COVID-19 manifestation. SARS-CoV-2 might infiltrate the CNS through the nose (Riel et al., 2015) and trigger a reactive immune response in the brain that could alter neuronal signalling. In addition, exposure of human brain organoids to SARS-CoV-2 revealed direct infection of neurons with subsequent alterations of intracellular signalling and cell death (Ackermann et al., 2020) that could disturb neuronal connectivity. Notably, TICS-M scores of post-COVID-19 patients did not significantly correlate with the maximal inflammatory response during the acute infection. Studies that investigated chronic fatigue syndrome in rheumatic disorders (Korte and Straub, 2019) and multiple sclerosis (Giovannoni, 2006) found that chronic but not acute dysregulation of the immune metabolism and especially cytokine composition correlated with fatigue and individual suffering.

Although, serum profiling during acute COVID-19 revealed distinct cytokine profiles that correlated with 9 disease outcome (Lucas et al., 2020) , detailed immunological profiling of post-COVID-19 patients is sparse. Our study is limited by the sample size. Therefore, we cannot report representative frequencies of post-COVID-19 manifestations and longitudinal monitoring and analysis of large cohorts of post-COVID-19 patients is warranted to find clear correlates with long-lasting symptoms after recovery.

Furthermore, we used the TICS-M that was originally developed to screen for MCI in elderly adults because we aimed to establish a tool that was validated for telephone interviews. Nonetheless, our test results should be validated by neuropsychological tests that were established in young adults such as the Cambridge Automated Test Battery (CANTAB) (Crooks et al., 2006) . Furthermore, confounders for cognitive testing such as years of education and substance abuse were not assessed. However, we documented the patients' profession and except for one participant who still visited high school all patients received at least 12 years of education. Moreover, only two patients received detailed neuropsychological and neurological assessment that confirmed the results of our screening as well as cranial MRI and lumbar puncture to exclude other potential pathologies. However, we provide a clear description of the observed deficits and provide distinct symptoms that will instruct prospective screenings in larger cohorts to sensitively identify post-COVID-19 patients with cognitive deficits.

Together, the results of our study demonstrate that young patients who recovered from uncomplicated COVID-19 can have sustained neuropsychologic deficits that can be unmasked by targeted screening.

Supplementary Material is available. PHQ-9 2.83 (0 -9) 0.7 (0 -2) 

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Telephone-based screening tools for mild cognitive impairment and dementia in aging studies: A review of validated instruments

The use of the modified telephone interview for cognitive status (Tics-M) in the detection of amnestic mild cognitive impairment

Cognitive domains associated with performance on the Telephone Interview for Cognitive Status-modified

Neuropsychiatric aspects of COVID-19 pandemic: A selective review

Neurological associations of COVID-19

Multiple sclerosis related fatigue

Extrapulmonary manifestations of COVID-19

Neurologic Features in Severe SARS-CoV-2 Infection

Anosmia in COVID-19 patients

Active Epstein-Barr virus infection in post-viral fatigue syndrome

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Utility of TICS-M for the assessment of cognitive function in older adults

Fatigue in inflammatory rheumatic disorders: Pathophysiological mechanisms

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort

Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease

Real-time tracking of selfreported symptoms to predict potential COVID-19

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Spectrum of neuropsychiatric manifestations in COVID-19

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Into the looking glass: Post-viral syndrome post COVID-19

Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

The olfactory nerve: A shortcut for influenza and other viral diseases into the central nervous system

The cognitive consequences of the COVID-19 epidemic: collateral damage?

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Neuropathological Features of Covid-19

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Endothelial cell infection and endotheliitis in COVID-19

We thank the UKE ID COVID-19 study team for their support. We thank members of the Friese and Schulze zur Wiesch laboratories for discussions. We thank Marc Lütgehetmann for providing PCR and antibody titres. We thank Stephanie Lau for helping with neuropsychological assessments. The graphical abstract was created using biorender.com. MAF received honoraria for consultation and travel expenses from Biogen, Merck KGaA, Novartis and Roche unrelated to this Correspondence.

No specific funding.

Manuel A. Friese: 0000-0001-6380-2420Julian Schulze zur Wiesch: 0000-0002- Marcel S. Woo: 0000-0002-1306-2708

The authors declare no competing interests.